Chen, Zhao <br/><br/>
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.  [electronic resource] 

 -  Nature  Mar 2012 
 - 613-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-4687 
<br/><br/><label>Standard No.: </label>10.1038/nature10937  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>AMP-Activated Protein Kinases<br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols<br/>Benzimidazoles--pharmacology<br/>Biomarkers, Tumor--genetics<br/>Clinical Trials, Phase II as Topic<br/>Disease Models, Animal<br/>Docetaxel<br/>Drug Evaluation, Preclinical<br/>Fluorodeoxyglucose F18<br/>Genes, p53--genetics<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>MAP Kinase Signaling System--drug effects<br/>Mice<br/>Mitogen-Activated Protein Kinase Kinases--antagonists & inhibitors<br/>Mutation--genetics<br/>Pharmacogenetics--methods<br/>Positron-Emission Tomography<br/>Protein Serine-Threonine Kinases--deficiency<br/>Proto-Oncogene Proteins--genetics<br/>Proto-Oncogene Proteins p21(ras)--genetics<br/>Randomized Controlled Trials as Topic<br/>Reproducibility of Results<br/>Taxoids--therapeutic use<br/>Tomography, X-Ray Computed<br/>Treatment Outcome<br/>ras Proteins--genetics